

Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance) (revoked)

TITLE III

**AUTHORISATION AND SUPERVISION OF
VETERINARY MEDICINAL PRODUCTS**

Chapter 3

Pharmacovigilance

.....

Textual Amendments applied to the whole legislation

- F1** Regulation revoked insofar as it applies to medicinal products for veterinary use (31.12.2020) by [The Veterinary Medicines and Animals and Animal Products \(Examination of Residues and Maximum Residue Limits\) \(Amendment etc.\) \(EU Exit\) Regulations 2019 \(S.I. 2019/676\)](#), regs. 1(2)(b), **5**; 2020 c. 1, **Sch. 5 para. 1(1)**
- Regulation revoked insofar as it applies to medicinal products for human use (31.12.2020) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2019 \(S.I. 2019/775\)](#), **Sch. 9 para. 1(h)** (subject to transitional provisions in [S.I. 2012/1916](#), **Sch. 33A**); 2020 c. 1, **Sch. 5 para. 1(1)**

Status:

Point in time view as at 31/12/2020.

Changes to legislation:

There are currently no known outstanding effects for the Regulation (EC) No 726/2004 of the European Parliament and of the Council, Chapter 3.